Tyrosine kinase inhibitors (TKI): imatinib

Evidence-based neurology checklist on tyrosine kinase inhibitors (tki): imatinib: Indications Philadelphia-chromosome positive chronic myeloid leukaemia (CML) KIT-positive gastrointestinal stromal tumours (GIST) Neurological complications Ophthalmic complications Dermatological complications…

Indications

  • Philadelphia-chromosome positive chronic myeloid leukaemia (CML)
  • KIT-positive gastrointestinal stromal tumours (GIST)

Neurological complications

Ophthalmic complications

Dermatological complications

Gastrointestinal complications

Hepatic complications

Cardiac complications

Respiratory complications

Other complications

Treatment of neurological complications

Acronym

References

  1. Rotstein DL, Sawicka K, Bharatha A, Montalban X, Lipton JH. CNS demyelination after initiating the tyrosine kinase inhibitor imatinib: A report of two cases. Mult Scler 2019 (Epub ahead of print).
  2. Feki J, Marrekchi G, Boudawara T, et al. Subdural hematoma during therapy of gastro-intestinal stromal tumor (GIST) with Imatinib mesylate. Gulf J Oncolog 2015; 1:92-95.
  3. Gulati AP, Saif MW. Retinal neovascularization and hemorrhage associated with the use of imatinib (Gleevec(®)) in a patient being treated for gastrointestinal stromal tumor (GIST). Anticancer Res 2012; 32:1375-1377.
  4. Rotstein DL, Sawicka K, Bharatha A, Montalban X, Lipton JH. CNS demyelination after initiating the tyrosine kinase inhibitor imatinib: A report of two cases. Mult Scler 2020; 26:1121-1124.
  5. Theodotou CB, Shah AH, Ivan ME, Komotar RJ. Subdural hematoma in a patient taking imatinib for GIST: a case report and discussion of risk with other chemotherapeutics. Anticancer Drugs 2016; 27:259-263.
  6. And 44 more. Subscribe to see the full list

Related checklists

Loading...